Please login to the form below
Balversa
This page shows the latest Balversa news and features for those working in and with pharma, biotech and healthcare.
J&J taps TARIS Biomedical for novel bladder cancer technology
J&J has a strong presence in the bladder cancer area, with its targeted bladder cancer drug Balversa (erdafitinib) gaining approval in the US earlier this year. ... With Balversa, a 99-patient study demonstrated a 40% overall response rate, 3% complete
Latest news
-
Incyte claims FDA priority review for bile duct cancer drug
Other FGFR inhibitors being tested for bile duct cancer include Johnson &Johnson’s Balversa (erdafitinib) – approved earlier this year for FGFR-mutated bladder cancer – as well as Bridge Bio’s infigratinib.
-
J&J’s targeted bladder cancer treatment gets US approval
Balversa is first FGFR inhibitor. Johnson &Johnson’s highly anticipated bladder cancer drug Balversa has been approved in the US, becoming the first personalised treatment targeting a certain type of genetic ... We recognise the significant unmet need
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Merck enters agreement with Hanmi for investigational NASH drug
- Novo Nordisk growth takes a hit with China deal
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- The gold standard of scientific evidence
- AbbVie creates new aesthetics division amid Allergan takeover
- EU approves bluebird bio’s CALD gene therapy Skysona
- Organon buys Forendo in $1bn deal
PMHub
Innovative Trials
Innovative Trials specialises in delivering effective global patient recruitment strategies for your clinical trials by adopting a patient and site-centric...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
